GSK2248761 + darunavir + ritonavir

GSK2248761 + darunavir + ritonavir is a combination of three orally administered small molecules for the treatment of HIV infection. GSK2248761 is an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by GSK. Darunavir is an HIV-1 protease inhibitor, and ritonavir is used as a pharmacokinetic enhancer (booster) to increase plasma concentrations of darunavir. Darunavir and ritonavir are widely used together in antiretroviral therapy and are generally co-administered with an additional antiretroviral agent. This triple combination would be expected to provide potent suppression of HIV replication by inhibiting two critical viral enzymes: reverse transcriptase (via GSK2248761) and protease (via darunavir, boosted by ritonavir).